Free Trial
NASDAQ:PRQR

ProQR Therapeutics Q3 2024 Earnings Report

ProQR Therapeutics logo
$2.24 +0.04 (+1.59%)
As of 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ProQR Therapeutics EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.12
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

ProQR Therapeutics Revenue Results

Actual Revenue
$4.22 million
Expected Revenue
$4.75 million
Beat/Miss
Missed by -$530.00 thousand
YoY Revenue Growth
N/A

ProQR Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
9:30AM ET

Upcoming Earnings

ProQR Therapeutics' Q2 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

ProQR Therapeutics Earnings Headlines

Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change.
See More ProQR Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProQR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProQR Therapeutics and other key companies, straight to your email.

About ProQR Therapeutics

ProQR Therapeutics (NASDAQ:PRQR) is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for the treatment of rare genetic disorders. Leveraging its proprietary RNA repair and editing platforms, the company designs therapeutic candidates that target the underlying molecular causes of disease by modulating RNA splicing, editing, or translation. ProQR’s early focus on ophthalmology and pulmonary applications has expanded into neuromuscular and other systemic indications, reflecting its commitment to tackling a broad range of inherited diseases with high unmet medical need.

The company’s flagship programs include sepofarsen (QR-110) for Leber congenital amaurosis type 10, which is an intravitreal RNA oligonucleotide designed to restore correct CEP290 protein expression in photoreceptor cells, and QR-421a for Usher syndrome and certain forms of retinitis pigmentosa, aimed at correcting splicing defects in the USH2A gene. In the pulmonary arena, ProQR is advancing QR-010, a therapeutic candidate for cystic fibrosis that seeks to repair the common F508del mutation in the CFTR gene. These programs underscore the versatility of ProQR’s RNA repair approach and its ability to address mutations unamenable to conventional small molecules or gene therapies.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR has established a presence in the United States with offices in Boston, Massachusetts. The company is led by Chief Executive Officer Matthew L. Davis, who brings extensive experience in biotech leadership and RNA therapeutics. The management team combines scientific expertise with drug development acumen, supported by a board of directors and advisory panels composed of clinicians, geneticists, and regulatory specialists.

ProQR pursues strategic collaborations and partnerships to accelerate clinical development and broaden its pipeline reach. Collaboration agreements with leading pharmaceutical and biotech organizations have provided access to complementary technologies and additional resources for advancing ProQR’s candidates through clinical trials. With an international footprint and a robust R&D engine, ProQR continues to drive toward regulatory milestones and potential first approvals, aiming to transform care for patients with inherited rare diseases worldwide.

View ProQR Therapeutics Profile

More Earnings Resources from MarketBeat